BioInformant - Stem Cell Industry News
LightNews LightNews
banner
bioinformant.bsky.social
BioInformant - Stem Cell Industry News
@bioinformant.bsky.social
180 followers 620 following 180 posts
As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.
Posts Replies Media Videos
bioinformant.bsky.social
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis - bioinformant.com/chu-toulouse...
CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis | BioInformant
Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close...
bioinformant.com
January 22, 2026 at 8:14 PM
bioinformant.bsky.social
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia - bioinformant.com/fda-approves...
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia | BioInformant
December 08, 2025, Silver Spring, MD (U.S. FDA) — The U.S. Food and Drug Administration announced that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) t...
bioinformant.com
January 19, 2026 at 7:33 AM
bioinformant.bsky.social
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - bioinformant.com/cellistic-ne...
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies | BioInformant
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy m...
bioinformant.com
January 15, 2026 at 12:57 AM
bioinformant.bsky.social
We continue to be awed by RoosterBio’s leadership in cell culture innovation and the way they simplify processes while enabling scalability:

Generate Billions of Xeno-Free Fibroblasts for Your R&D Program:
www.roosterbio.com/products/xen...
Xeno-Free RoosterVial™-hDF
Available in both 1M or 10M cell per vial formats to meet your needs throughout product development. Trilineage differentiation of a representative XF RoosterVial-hAD lot.
www.roosterbio.com
January 13, 2026 at 10:58 PM
bioinformant.bsky.social
WORD+2026 Connecting Global NAM Research. #Bettertogether Organoids, Organ-on-a-Chip, Assembloids and innovative NAMS - bioinformant.com/word2026/

In just three weeks time, the 5th WORD+ event brings together leading researchers, societies and technologies in Cambridge, U.K.
January 13, 2026 at 10:01 PM
bioinformant.bsky.social
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts” - bioinformant.com/the-jackson-...
@jacksonlab.bsky.social
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered "virtual hearts" | BioInformant
New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trials BAR HARBOR, Maine, Dec. 8, 2025 — Developing new drugs is one of the riskiest and most...
bioinformant.com
January 13, 2026 at 7:00 AM
bioinformant.bsky.social
Kobe University Introduces a Simplified Cryopreservation Method for iPSCs - bioinformant.com/kobe-univers...
Kobe University Introduces a Simplified Cryopreservation Method for iPSCs | BioInformant
Researchers at Kobe University have unveiled a novel cryopreservation technique that could meaningfully streamline how induced pluripotent stem cells (iPSCs) are stored and handled in laboratory setti...
bioinformant.com
January 12, 2026 at 12:39 AM
bioinformant.bsky.social
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...

@bristolmyerssquibb.bsky.social @astra-zeneca.bsky.social
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering | BioInformant
Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body ...
bioinformant.com
January 11, 2026 at 9:41 AM
bioinformant.bsky.social
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions - bioinformant.com/thewell-bios...
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions | BioInformant
Monmouth Junction, NJ and Tokyo, Japan — January 7, 2026 — TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a lead...
bioinformant.com
January 10, 2026 at 12:04 PM
bioinformant.bsky.social
10 Cell Therapy Stocks That Will Be Intriguing to Watch in 2026 - bioinformant.com/cell-therapy...
@vistagen.bsky.social
10 Cell Therapy Stocks That Will Be Intriguing to Watch in 2026
Interesting in cell therapy companies doing transformative work? Discover 10 companies that are developing intriguing technologies.
bioinformant.com
January 9, 2026 at 1:18 PM
bioinformant.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL:
A Cost-Optimized Approach - bioinformant.com/gmp-manufact...
@reprocell.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
bioinformant.com
January 7, 2026 at 12:47 PM
bioinformant.bsky.social
Congratulations to the PeptiGrowth Inc. team on the launch of its IL-15 alternative peptide, an exciting advance in synthetic growth factor technology.

PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide: bioinformant.com/peptigrowth-...
PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide | BioInformant
January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptid...
bioinformant.com
January 6, 2026 at 7:55 PM
bioinformant.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - bioinformant.com/novo-withdra...
@novonordisk.bsky.social
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential | BioInformant
Sadly, Novo Nordisk has ended its $598 million collaboration with Tokyo-based biotech Heartseed, marking a major shift in its approach to regenerative medicine and iPSCs, specifically.  The cancelled ...
bioinformant.com
January 2, 2026 at 2:03 AM
bioinformant.bsky.social
Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery - bioinformant.com/curi-bio-sec...
@curibio.bsky.social
Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery | BioInformant
Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data ana...
bioinformant.com
December 30, 2025 at 1:42 AM
bioinformant.bsky.social
What has 2025 taught us about stem cell innovation and market dynamics? - bioinformant.com/stem-cell-in...
What has 2025 taught us about stem cell innovation and market dynamics? | BioInformant
What has 2025 taught us about stem cell innovation and market dynamics? For cell therapy professionals, 2025 has been a defining year, not because it produced a single breakthrough, but because it cla...
bioinformant.com
December 27, 2025 at 8:27 AM
bioinformant.bsky.social
BMS Makes a Bold Leap into CAR-T Buying Orbital Therapeutics for $1.5B - bioinformant.com/bms-makes-a-...
@bristolmyerssquibb.bsky.social
BMS Makes a Bold Leap into CAR-T Buying Orbital Therapeutics for $1.5B | BioInformant
On October 10th, 2025, Bristol Myers Squibb (BMS) announced its plan to acquire Orbital Therapeutics for 1.5 billion dollars in cash. This decisive move places BMS directly into the rapidly growing in...
bioinformant.com
December 21, 2025 at 10:33 PM
bioinformant.bsky.social
A Spark Becomes a Surge: How Ryoncil Reignited MSC Development - bioinformant.com/yoncil-reign...
A Spark Becomes a Surge: How Ryoncil Reignited MSC Development | BioInformant
It’s official: Today marks precisely one year since the cell therapy field celebrated a historic milestone. On December 18, 2024, the FDA granted its first-ever approval for a Mesenchymal Stem Cell (M...
bioinformant.com
December 19, 2025 at 5:06 AM
bioinformant.bsky.social
Who Is CryoHoldco? Latin America’s Largest Cord Blood Bank - bioinformant.com/who-is-cryoh...
Who Is CryoHoldco? Latin America's Leading Cord Blood Bank
CryoHoldco is a stem cell bank holding company that is the market leader in Latin America and one of the top 10 largest cord blood banks in the world.
bioinformant.com
December 18, 2025 at 10:42 AM
bioinformant.bsky.social
A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities - bioinformant.com/ipsc-core-fa...
@cornelluniversity.bsky.social @harvard.edu @mit.edu @scicambridge.bsky.social @salkinstitute.bsky.social
A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities | BioInformant
Induced pluripotent stem cell (iPSC) core facilities are facilities created to facilitate the derivation and distribution of iPSC lines. These facilities promote iPSC research advances by providing di...
bioinformant.com
December 15, 2025 at 12:00 PM
bioinformant.bsky.social
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy - bioinformant.com/stem-cell-th...
The Future of Stem Cell Therapeutics - Balancing Safety and Efficacy
With 5,000+ stem cell trials ongoing worldwide, what do we actually know about the safety and efficacy of stem cell therapeutics?
bioinformant.com
December 12, 2025 at 9:52 PM
bioinformant.bsky.social
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting #Exosome Drug Delivery Platform - bioinformant.com/esco-aster-s...
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform | BioInformant
Singapore, 12 December 2025 – Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targe...
bioinformant.com
December 12, 2025 at 3:28 AM
Reposted by BioInformant - Stem Cell Industry News
bioinformant.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach

REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.

bioinformant.com/gmp-manufact...

@reprocell.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
bioinformant.com
December 2, 2025 at 4:43 PM
bioinformant.bsky.social
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - bioinformant.com/big-pharma-c...
@abbvie.bsky.social @bristolmyerssquibb.bsky.social @astra-zeneca.bsky.social
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering | BioInformant
Across 2025, a striking trend has emerged in biotechnology. Major pharmaceutical companies are racing to acquire in vivo cell engineering platforms, signaling that reprogramming cells inside the body ...
bioinformant.com
December 4, 2025 at 11:52 AM
bioinformant.bsky.social
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer - bioinformant.com/aabb-certifi...
@aabbupdates.bsky.social
AABB To Run Limited-Time Certified Advanced Biotherapies Professional (CABP) Free Exam Retake Offer | BioInformant
December 2, 2025, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce a limited-time Certified Advanced Biotherapies Professional (CABP) free exam ...
bioinformant.com
December 3, 2025 at 10:43 AM
bioinformant.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach

REPROCELL functions as a true one-stop stem cell biotech, unifying the entire #iPSC value chain under a single, dependable partner.

bioinformant.com/gmp-manufact...

@reprocell.bsky.social
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
bioinformant.com
December 2, 2025 at 4:43 PM